Fully Characterized, Standardized Human Induced Pluripotent Stem Cell Line and Ready-to-Use, High-Quality Neural Progenitor Cells for Downstream Differentiation Applications
On June 29, 2023, STEMCELL Technologies' Dr. Andrew Gaffney and Dr. Erin Knock presented on how to streamline PSC-related workflows using highly characterized induced pluripotent stem cells (iPSCs) and neural progenitor cells (NPCs), and how to differentiate these cells into a variety of cell types downstream. In this Q&A report, you can read their answers to questions asked by the audience. Answers have been edited for length and/or clarity.
Cellular Brain Repair for Parkinson’s Disease: Is the Answer in the (Biomaterial) Matrix?
Join Eilís Dowd, PhD who will highlight her lab's recent data demonstrating that dopaminergic cell replacement in the Parkinsonian rodent brain, using both fetal and induced stem cell-derived cells, is enhanced when the cells are transplanted in a neurotrophin-enriched collagen hydrogel.
Fully Characterized, Standardized Human Induced Pluripotent Stem Cell Line and Ready-to-Use, High-Quality Neural Progenitor Cells for Downstream Differentiation Applications
In this webinar, experts present a standardized human induced pluripotent stem cell line and its differentiation into neural cells for disease modeling and assay development.
